Genspera, Inc. announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin"for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer). Mipsagargin was also recommended by the United States Adopted Names Council (USAN) of the American Medical Association. GenSpera recently released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib.

Data showed 80% of patients treated with mipsagargin had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at four months on study. In addition, imaging analysis demonstrated an impressive blockade of tumor blood flow in the single patient evaluated by this method to date.